Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Epitracker Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are evenly spread across 3 distinct examiners and 3 distinct art units, meaning each examiner is responsible for exactly one action. This distribution suggests that the company's prosecution efforts are diversified across different specialized groups within the USPTO.
The busiest examiner, WEDDINGTON, KEVIN E, is assigned 1 pending office action. Since each of the 3 distinct examiners handles only 1 pending office action, no single individual has a disproportionate impact on the portfolio. The practitioner must therefore prepare for 3 different examination styles across the 3 distinct art units, as each examiner will bring their own interpretation to the Biotechnology & Pharmaceuticals claims.
Managing 3 pending office actions requires the practitioner to track 3 separate timelines and sets of requirements. Because the actions are in 3 distinct art units, there is a possibility of encountering different procedural nuances. The practitioner should ensure that the arguments made to WEDDINGTON, KEVIN E and the other examiners remain consistent with the company's broader intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.8% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18623536 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | LEE, WILLIAM Y | — |
| 18309998 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | COLEMAN, BRENDA LIBBY | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1623 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18667970 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | WEDDINGTON, KEVIN E | 1629 | §112Other | Non-Final OA | — | Pending | May 17, 2024 |
| 18623536 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | LEE, WILLIAM Y | 1623 | §103§112DP | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18309998 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | — | Pending | May 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEpitracker Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Kevin E Weddington has the most, with 1 of Epitracker Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
